High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy

Summary: Hyperglycemia is a recognized risk factor for bladder cancer (BC). Enfortumab vedotin (EV), the first NECTIN4-targeting antibody-drug conjugate, demonstrates promising clinical efficacy in patients with advanced BC. In this study, we show that EV treatment is less effective in BC patients w...

Full description

Bibliographic Details

Published in:	Cell Reports
Main Authors:	Zhuo Xing, Tiejun Yang, Xurui Li, Haozhe Xu, Yulong Hong, Shuai Shao, Tao Li, Liefu Ye, Yuan Li, Xin Jin, Yongbao Wei
Format:	Article
Language:	English
Published:	Elsevier 2025-04-01
Subjects:	CP: Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S221112472500316X